• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare

    8/14/25 11:10:00 AM ET
    $NVTA
    Medical Specialities
    Health Care
    Get the next $NVTA alert in real time by email

    SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch.

    Citizen Health announces $14.5 million seed funding
and strategic partnership to transform the health
experience for patients with rare and complex conditions. (PRNewsfoto/Citizen Health)

    Founded by Farid Vij (CEO & Co-founder), Nasha Fitter (Chief Business Officer & Co-founder), and a team of industry veterans, Citizen Health is pioneering a new paradigm in healthcare by empowering patients—especially those with rare and complex conditions—with agency, clarity, and actionable insights. The company's platform combines AI, community, and longitudinal health data to help patients interpret medical records, track symptoms, learn from peers, manage appointments, and connect to the next best step in their health journey.

    "Today's patients aren't waiting—they're searching, deciding, and expecting more," said Farid Vij, CEO and co-founder of Citizen Health. "They deserve the same clarity, personalization, and intelligence in healthcare that they get in every other part of their lives. At Citizen, we're building a personalized AI Advocate for every patient that not only helps people make sense of their health journey, but actually guides them to what they should do next—and connects them to it. This is about turning passive systems into proactive, human-centered experiences."

    Nearly half of American adults have at least one chronic illness, making self-advocacy especially important. Citizen's ultimate vision is to provide every patient with a personalized AI Advocate, turning fragmented care into a connected, proactive, and precise experience. They are building agentic AI to take initiative, identifying and acting on opportunities to improve health in ways patients themselves might not anticipate.

    "We backed Citizen because they are redefining the care model for patients with complex disease. Citizen's AI advocate is the foundation of a pioneering patient and caregiver experience that is already helping thousands of Americans answer previously unanswerable questions, make informed medical decisions, and accelerate new cures," said Sebastian Caliri, Partner at 8VC who led the Series A round and joined the Citizen Board of Directors.

    Vij and Fitter met at their previous company Citizen, which was acquired by Invitae (NYSE:NVTA) in 2021, where Vij was a co-founder. Their new venture, Citizen Health, brings together a leadership team with deep expertise in AI, healthcare, privacy, and consumer technology, with personal motivations rooted in rare disease advocacy and patient empowerment.

    "Citizen has truly created a groundbreaking platform that supports individual patients looking to manage rare and complex diseases, while also giving patient advocacy groups a better way to organize their data, and pharma leaders a better way to utilize that data for drug discovery and trials," added Mathias Schilling, Founding Partner at Headline who also invested in the round. "It's rare to see a company combining such expertise in AI and consumer design to impact healthcare, and we're proud to back Farid, Nasha, and the rest of the team."

    Citizen Health's Traction and Momentum

    • Built over 60 engaged communities across 123 rare and complex conditions
    • Partnered with 70+ patient advocacy groups, 70% of which joined organically
    • 98.3% of patients share data for research, reflecting high trust in the platform
    • Data already accepted by the FDA for regulatory submission
    • Collaborating with over 10 pharmaceutical partners

    With rare diseases affecting over 400 million people globally and 95% still lacking approved treatments, Citizen Health's mission is more urgent than ever. The company's approach aligns with recent FDA calls for innovation in rare disease and addresses challenges posed by shifting NIH funding and regulatory uncertainty. As genetic testing becomes more accessible, Citizen Health's platform offers a critical solution for new disease groups seeking connection and data-driven progress.

    Citizen Health will launch the first version of its AI Advocate to select communities in Q3, alongside a new product for patient advocacy groups. The company's primary focus is recruiting top AI engineers, product builders, and designers to accelerate its mission, as well as deepening partnerships with pharma, policymakers, and patient organizations.

    About Citizen Health

    Citizen Health is building the future of healthcare, starting with rare disease. By combining AI, community, and longitudinal data, Citizen empowers patients to take control of their care and contribute to the richest research-grade dataset in healthcare. The company is headquartered in San Francisco, CA, and backed by leading investors including 8VC, Headline, Transformation Capital, the Chan Zuckerberg Initiative, and prominent angels. For more information, visit https://www.citizen.health.

    About 8VC

    8VC is a leading technology investment firm. Its partners have co-founded companies including Palantir, Addepar, Resilience, and Saronic, and invested in such healthcare innovators such as Oscar, Cityblock, and Candid Health. 8VC manages over $7 billion in committed capital, focusing on smart enterprise platforms, healthcare, logistics, Bio-IT, and defense. For more information, visit https://8vc.com.

    About Headline

    Founded in 1998, Headline is a venture capital firm that partners with fast-growing technology teams to make their success global. With more than $4B of assets under management, the firm invests from its network of regionally focused early-stage funds across the US, Europe, Asia, and Latin America. Headline's Global Growth Fund invests globally from Series B and beyond. The size and locations of these funds allow the firm to see local trends up close, meet winning founders, and lead rounds at every stage. Among the 300+ investments globally, Headline's portfolio includes Acorns, AppFolio, ANGI (FKA Angie's List), Brite Payments, Bumble, Fetch, Gopuff, Honeycomb, LucidLink, Mistral AI, Monta, NGINX, Raisin, Sonos, Segment, SEMrush, and Staffbase.

    For media inquiries or more information, please contact:

    Steven Le

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citizen-health-raises-30-million-to-build-ai-advocate-for-every-patient-ushering-in-a-new-era-of-patient-centered-healthcare-302529736.html

    SOURCE Citizen Health

    Get the next $NVTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVTA

    DatePrice TargetRatingAnalyst
    7/5/2023Underweight
    JP Morgan
    5/15/2023Mkt Perform → Underperform
    Raymond James
    1/31/2023$2.00Neutral → Sell
    Goldman
    8/25/2022$1.00Underperform
    Credit Suisse
    8/10/2022Neutral → Underweight
    JP Morgan
    7/26/2022$8.00 → $2.50Outperform → Market Perform
    Cowen
    7/21/2022Outperform → Mkt Perform
    Raymond James
    7/20/2022Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $NVTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nussbaum Robert L covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 3% to 551,941 units (SEC Form 4)

    4 - Invitae Corp (0001501134) (Issuer)

    12/21/23 9:20:16 PM ET
    $NVTA
    Medical Specialities
    Health Care

    Brida Thomas covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 2% to 916,183 units (SEC Form 4)

    4 - Invitae Corp (0001501134) (Issuer)

    12/21/23 9:14:33 PM ET
    $NVTA
    Medical Specialities
    Health Care

    Sholehvar David was granted 850,000 shares (SEC Form 4)

    4 - Invitae Corp (0001501134) (Issuer)

    11/14/23 7:58:49 PM ET
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Invitae

    JP Morgan resumed coverage of Invitae with a rating of Underweight

    7/5/23 7:28:43 AM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae downgraded by Raymond James

    Raymond James downgraded Invitae from Mkt Perform to Underperform

    5/15/23 7:28:13 AM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae downgraded by Goldman with a new price target

    Goldman downgraded Invitae from Neutral to Sell and set a new price target of $2.00

    1/31/23 6:15:23 AM ET
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Invitae Corporation

    25-NSE - Invitae Corp (0001501134) (Subject)

    2/21/24 8:59:54 AM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Invitae Corp (0001501134) (Filer)

    2/14/24 6:59:56 AM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Invitae Corp (0001501134) (Filer)

    2/6/24 5:07:32 PM ET
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare

    SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch. Founded by Farid Vij (CEO & Co-founder), Nasha Fitter (Chief Business Officer & Co-founder), and a team of industry veterans, Citizen Health is pioneering a new paradigm in healthcare by empowering patients—especially those with

    8/14/25 11:10:00 AM ET
    $NVTA
    Medical Specialities
    Health Care

    Labcorp Announces Winning Bid for Select Assets of Invitae

    Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

    4/24/24 9:27:00 PM ET
    $LH
    $NVTA
    Medical Specialities
    Health Care

    Invitae Enters into Agreement with Labcorp for Sale of Business

    – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

    4/24/24 9:19:00 PM ET
    $LH
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Reproductive Health Assets from Invitae

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o

    1/22/24 7:00:00 AM ET
    $NTRA
    $NVTA
    Medical Specialities
    Health Care

    Invitae Reports Second Quarter 2023 Financial Results

    – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res

    8/8/23 4:01:00 PM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

    SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

    7/26/23 4:01:00 PM ET
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    Leadership Updates

    Live Leadership Updates

    View All

    Aranscia Acquires YouScript from Invitae

    Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc

    11/15/23 4:35:00 PM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

    SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.  www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu

    9/25/23 4:30:00 PM ET
    $NVTA
    Medical Specialities
    Health Care

    Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

    – Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth –  SAN FRANCISCO, Aug. 28, 2023  /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of

    8/28/23 4:02:00 PM ET
    $NVTA
    Medical Specialities
    Health Care

    $NVTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

    SC 13G/A - Invitae Corp (0001501134) (Subject)

    2/13/24 5:07:58 PM ET
    $NVTA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

    SC 13G/A - Invitae Corp (0001501134) (Subject)

    2/13/24 9:10:56 AM ET
    $NVTA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

    SC 13G/A - Invitae Corp (0001501134) (Subject)

    2/5/24 6:08:57 AM ET
    $NVTA
    Medical Specialities
    Health Care